Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker (AUR)

This study has been completed.
Sponsor:
Information provided by:
Franklin D. Gaylis, MD Inc.
ClinicalTrials.gov Identifier:
NCT00680680
First received: May 16, 2008
Last updated: May 19, 2008
Last verified: May 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2008
  Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)